Therapeutic Advances in Neurological Disorders (TAND) 是经同行评议的开放获取期刊，出版神经科学各个领域的前沿探索和创新研究。
• 被收录于PubMed、Web of Science – Science Citation Index Expanded (SCIE)、Scopus 和 Directory of Open Access Journals (DOAJ)
• Impact Factor: 3.580
• Listed in PubMed and indexed in Web of Science, Science Citation Index Expanded (SCIE), Scopus and Directory of Open Access Journals (DOAJ)
• A leading gold open access journal in Clinical Neurology
• Average time from submission to first decision is 36 days
• Rapid online publication
• Over 1 million full article views annually
Therapeutic Advances in Neurological Disorders
Impact Factor 3.580
Special Collection on Autoimmune NeurologyIn order for your paper to be considered for inclusion, please submit by 1 October 2019.
Autoimmune neurology refers to a number of acute or subacute neurological diseases affecting the whole neuraxis. Over the past decade, the identification of these disorders was made possible by the discovery of specific autoantibodies directed against synaptic antigens and voltage-gated or water channels. These antibodies define distinct syndromes that, in spite of their variable symptomatology, all respond to immunotherapies.
The field of autoimmune neurology, although new and evolved in the past decade, has already made an important impact in neurology and neurologic therapeutics by identifying potentially treatable but previously unrecognized disorders. The groups of autoimmune disorders covered in the collection include but are not limited to:
Following initial triage, suitable manuscripts submitted to this Special Collection will undergo external peer review. Usual article processing charge (APC) applies.
Diseases affecting synaptic antigens, such as autoimmune encephalitis and stiff person syndrome
Diseases affecting voltage-gated potassium channels, such as limbic encephalitis, Morvan syndrome and neuromyotonia
Diseases affecting water channels, such as neuromyelitis optica spectrum disorders (NMOSDs)
Autoimmune paraneoplastic syndromes
Autoimmune neurological disorders triggered by immune check-point inhibitors as applied in advanced malignancies
Autoimmune encephalitides triggered by known viral infections, such as herpes zoster
Manuscript Deadline: 1 October 2019
Guest Editor: Professor Marinos C. Dalakas (Marinos.Dalakas@jefferson.edu), Thomas Jefferson University, Philadelphia, USA